Company Filing History:
2 out of 8,373 
1 out of 62 
1 out of 504 
Years Active: 2018-2023
Title: Christopher Boyce Burge: Innovator in Gene Expression and Cancer Research
Introduction
Christopher Boyce Burge is a notable inventor based in Belmont, MA (US). He has made significant contributions to the field of gene expression and cancer research, holding a total of 2 patents. His work focuses on innovative methods for gene silencing and activation, as well as the identification of prognostic indicators for metastatic cancer.
Latest Patents
Burge's latest patents include "Splicing-dependent transcriptional gene silencing or activation." This invention discloses methods for inhibiting or activating the transcription of a gene of interest using antisense oligonucleotides and/or small molecules. Additionally, it describes methods for enhancing gene expression by creating new splice sites in a gene within a cell. Another significant patent is "Alternatively spliced mRNA isoforms as prognostic indicators for metastatic cancer." This invention provides a method for identifying tumors likely to metastasize by quantifying alternatively spliced mRNA isoforms of specific genes in tumor samples.
Career Highlights
Throughout his career, Burge has worked with prestigious institutions such as the Massachusetts Institute of Technology and Montefiore Medical Center. His research has contributed to advancements in understanding gene regulation and cancer progression.
Collaborations
Burge has collaborated with notable colleagues, including Frank B. Gertler and Irina M. Shapiro. Their combined expertise has furthered research in the fields of molecular biology and oncology.
Conclusion
Christopher Boyce Burge is a distinguished inventor whose work in gene expression and cancer research has led to valuable patents and collaborations. His innovative approaches continue to impact the scientific community and advance our understanding of complex biological processes.